Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Stock Information for Journey Medical Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Journey Medical Corporation

Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs
Akebia Therapeutics to Present at Upcoming Investor Conferences
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients
Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.